Beatrice Knudsen, MD, PhD
![Beatrice Knudsen, MD, PhD](https://res.cloudinary.com/pcf/images/w_174,h_243,c_scale/fl_lossy/f_auto,q_auto/v1674666193/Beatrice-Knudsen-MD-PhD-from-google_552221138/Beatrice-Knudsen-MD-PhD-from-google_552221138.jpg?_i=AA)
About Beatrice Knudsen, MD, PhD
Biomarkers of Response to Treatment with XL184 in the Bone
XL184 (caboxantanib) is a new experimental medication for metastatic prostate cancer with promising clinical results. To more effectively administer XL184 to patients with metastatic prostate cancer, Dr. Knudsen seeks to define the precise anti-cancer mechanism of action. She has assembled a team at Cedars-Sinai in Los Angeles and University of Washington/Fred Hutchinson Cancer Institute in Seattle to study the effects of XL184 in patient biopsies and will investigate the mechanism of action of this encouraging agent as a biomarker for response in patients.
Potential patient benefit: An understanding of the mechanism of action of XL184 will accelerate the clinical development of this very encouraging agent by providing investigators with laboratory and imaging biomarkers of response.
Institution
Cedars-Sinai Medical Center
Discipline
Pathology